USE OF CANNABIDIOL IN AUTISM SPECTRUM DISORDER: EVIDENCE AND THERAPEUTIC PERSPECTIVES
DOI:
https://doi.org/10.36489/saudecoletiva.2026v18i111p20554-20567Keywords:
Autistic Disorder, Autism Spectrum Disorder, Cannabidiol, Pharmacological Treatment, CannabisAbstract
Objective: This article aims to highlight the results obtained through clinical studies in the management of clinical manifestations in patients with autism. Methods: Integrative literature review. Three databases were used: PubMed, LILACS, and SciELO. Results: Combined cannabidiol treatment demonstrated better results in several aspects related to the manifestations of the disorder that affect the quality of life of the individual. Despite the excellent results, side effects appeared such as increased or decreased appetite, insomnia or drowsiness, diarrhea, and irritability. Conclusion: The findings suggest that the use of cannabidiol may be a promising approach for managing autism symptoms, with a relatively favorable safety profile. However, long-term studies are needed to validate its efficacy and safety.
References
American Psychiatric Association. Manual diagnóstico e estatístico de transtornos mentais: DSM-5. 5ª ed. Porto Alegre: Artmed; 2014.
Lai MC, Kassee C, Besney R, Bonato S, Hull L, Mandy W, et al. Prevalence of co-occurring mental health diagnoses in the autism population: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(10):819-829. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31447415/
World Health Organization. Autism spectrum disorders. Geneva: WHO; 2023. Disponível em: https://www.who.int/en/news-room/fact-sheets/detail/autism-spectrum-disorders
Zeidan J, Fombonne E, Scorah J, Ibrahim A, Durkin MS, Saxena S, et al. Global prevalence of autism: a systematic review update. Autism Res. 2022;15(5):778-790. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35238171/
Jaschke AC, Howlin C, Pool J, Greenberg YD, Atkinson R, Kovalova A, et al. Study protocol of a randomized control trial on the effectiveness of improvisational music therapy for autistic children. BMC Psychiatry. 2024;24(1):637. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39334042/
Kuroda M, Kawakubo Y, Kamio Y, Yamasue H, Kono T, Nonaka M, et al. Preliminary efficacy of cognitive-behavioral therapy on emotion regulation in adults with autism spectrum disorder: a pilot randomized waitlist-controlled study. PLoS One. 2022;17(11):e0277398. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36417403/
Beavers A, Fleming A, Shahidullah JD. Animal-assisted therapies for autism. Curr Probl Pediatr Adolesc Health Care. 2023;53(11):101478. Disponível em: https://pubmed.ncbi.nlm.nih.gov/37996312/
Fundação Oswaldo Cruz. Uso de canabinoides no tratamento de doenças: uma revisão crítica. Rio de Janeiro: Fiocruz; 2023. Disponível em: https://portal.fiocruz.br/sites/portal.fiocruz.br/files/documentos_2/nt_canabinoides_20230419.pdf
Gonçalves GAM, Schlichting CLR. Efeitos benéficos e maléficos da Cannabis sativa. Uningá Review. 2014;20(1). Disponível em: https://revista.uninga.br/uningareviews/article/view/1560
Batalla A, Bos J, Postma A, Bossong MG. The impact of cannabidiol on human brain function: a systematic review. Front Pharmacol. 2021;11:618184. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33551817/
Silva Junior EA, Medeiros WMB, Santos JPM, Sousa JMM, Costa FB, Pontes KM, et al. Avaliação da eficácia e segurança do extrato de cannabis rico em canabidiol em crianças com transtorno do espectro autista: ensaio clínico randomizado, duplo-cego e controlado por placebo. Trends Psychiatry Psychother. 2024;46:e20210396. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35617670/
Pretzsch CM, et al. Effects of cannabidiol on brain excitation and inhibition systems: a randomized placebo-controlled single-dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology. 2019;44(8):1398-1405. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30758329/
Barchel D, et al. Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and comorbidities. Front Pharmacol. 2019;9:1521. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30687090/
Fleury-Teixeira P, Caixeta FV, Silva LCR, Brasil-Neto JP, Malcher-Lopes R. Effects of Cannabis sativa extract enriched with cannabidiol on autism spectrum disorder symptoms: an observational study of 18 participants undergoing compassionate use. Front Neurol. 2019;10:1145. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31736860/
Siani-Rose M, et al. Cannabis-responsive biomarkers: a pharmacometabolomics-based application to evaluate the impact of medical cannabis treatment on children with autism spectrum disorder. Cannabis Cannabinoid Res. 2023;8(1):126-137. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34874191/
Schleider LBL, et al. Real-life experience of medical cannabis treatment in autism: analysis of safety and efficacy. Sci Rep. 2019;9(1):200. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30655581/
Gonçalves GAM, Schlichting CLR. Clinical and family implications of cannabidiol (CBD)-dominant full-spectrum phytocannabinoid extract in children and adolescents with moderate to severe non-syndromic autism spectrum disorder. Molecules. 2022;17(6):686. Disponível em: https://www.mdpi.com/1424-8247/17/6/686
Silva de Mendonça S. Transtorno do espectro autista e acessibilidade amorosa. 2022. Disponível em: https://www.researchgate.net/profile/Sophia-Silva-De-Mendonca/publication/357992127
Silva MJ, Sousa JC. O impacto da tecnologia no transtorno do espectro autista: uma abordagem multidisciplinar. 2024. Disponível em: https://www.anpec.org.br/sul/2024/submissao/files_I/i1-61e6cc12059ee38dfe51a0e2508d6237.pdf
Brasil. Ministério da Educação. Instituto Nacional de Estudos e Pesquisas Educacionais Anísio Teixeira. Censo da educação superior: sinopse estatística da educação superior 2018. Brasília: INEP; 2019. Disponível em: http://portal.inep.gov.br/web/guest/sinopses-estatisticas-da-educacao-superior
Silva MJ, Sousa JC. Desafios e oportunidades: o transtorno do espectro autista no mercado de trabalho. 2024. Disponível em: https://www.anpec.org.br/sul/2024/submissao/files_I/i1-61e6cc12059ee38dfe51a0e2508d6237.pdf
World Health Organization. International classification of diseases (ICD-11). Geneva: WHO; 2019. Disponível em: https://icd.who.int/
Silva MCA. Meninas e mulheres com transtorno do espectro do autismo: diagnósticos, reconhecimentos e vivências. 2022. Disponível em: https://repositorio.ufscar.br/bitstream/handle/ufscar/15923
Doubrawa D, Menezes KAS. Importância do diagnóstico precoce do autismo: uma revisão de literatura. Braz J Dev. 2023;9(6):1-10. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BRJD/article/view/60660
Gonzalez MC, Herrmann HJ, Kertesz J, Vicsek T. Community structure and ethnic preferences in school friendship networks. Physica A. 2007;373(1):641-650.
Silva Junior EA, et al. Cannabis and cannabinoid use in autism spectrum disorder: a systematic review. Trends Psychiatry Psychother. 2022;44:e20200149. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34043900/
Silva Junior EA, et al. Cannabis and cannabinoid use in autism spectrum disorder: a systematic review. Trends Psychiatry Psychother. 2022;44:e20200149. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34043900/
Pedrazzzi JFC, et al. Cannabidiol for the treatment of autism spectrum disorder: hope or hype? Psychopharmacology. 2022;239(9):2713-2734. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35904579/
Francischetti EA, Abreu VG. O sistema endocanabinóide: nova perspectiva no controle de fatores de risco cardiometabólico. Arq Bras Cardiol. 2006;87(4):389-396. Disponível em: https://www.scielo.br/j/abc/a/kqZfp3s75d4YwsxfPXWbv7m/
